Regencell Bioscience
RGC
7.11
-0.24
-3.27%
Regencell Bioscience
US · RGC
#2393 by market cap
Listed 2021
7.11
-0.24
-3.27%
Live - 5344 symbols - heartbeat 218s ago
· 2026-10-08 05:07
Pre-market
7.20
+1.27%
After-hours
7.11
0.00%
Overnight
6.89
-3.09%
- Market cap
- 3.53B
- P/E (TTM)i
- -296.25
- P/Bi
- 263.33
- EPSi
- -0.02
- Div yieldi
- 0.00%
- 52W posi
- 4%
Reader sentiment
Are you bullish or bearish on RGC?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Margins
Income statement
| Line item | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | 1.97B | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 513.40M | 162.77K | 426.14K | 943.04K | 5.11M | 4.69M | 3.67M | 2.82M |
| Research & development | -- | 228.22K | 386.23K | 438.32K | 2.51M | 1.58M | 1.07M | 948.29K |
| Operating profit | 271.70M | -390.99K | -812.37K | -1.38M | -7.62M | -6.27M | -4.74M | -3.77M |
| Pretax profit | 213.90M | -390.99K | -812.37K | -1.35M | -7.59M | -6.06M | -4.36M | -3.58M |
| Tax | 101.60M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 112.30M | -390.99K | -812.37K | -1.35M | -7.59M | -6.06M | -4.36M | -3.58M |
| Basic EPS | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.72 | 0.00 | 0.00 | 0.00 | -0.02 | -0.01 | -0.01 | -0.01 |
| Line item | 2023-06 | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -- | -- | -- | -- | -- | -- |
| Pretax profit | -- | -- | -- | -- | -- | -- |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -- | -- | -- | -- | -- | -- |
| Basic EPS | -- | -- | -- | -- | -- | -- |
| Diluted EPS | -- | -- | -- | -- | -- | -- |
Balance sheet
| Line item | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 463.30M | 243.31K | 386.98K | 66.85K | 16.44M | 11.62M | 8.11M | 4.90M |
| Cash & ST investments | 228.80M | 243.31K | 386.98K | 59.41K | 16.42M | 11.56M | 7.96M | 4.90M |
| Inventory | 22.90M | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 2.84B | 243.31K | 514.02K | 340.13K | 18.02M | 12.62M | 8.44M | 5.76M |
| Total current liabilities | 561.40M | 2.08M | 3.16M | 4.34M | 577.76K | 606.91K | 193.58K | 663.67K |
| Short-term debt | 26.60M | 2.08M | 3.07M | 3.68M | 410.99K | 438.26K | 59.81K | 312.78K |
| Long-term debt | 2.34B | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 3,698,700,000.00 | 2,081,828.00 | 3,164,910.00 | 4,337,771.00 | 938,032.00 | 632,320.00 | 219,512.00 | 895,308.00 |
| Total equity | -855.80M | -1.84M | -2.65M | -4.00M | 17.08M | 11.99M | 8.22M | 4.86M |
| Retained earnings | 70.90M | -1.84M | -2.65M | -4.00M | -11.44M | -17.32M | -21.62M | -25.20M |
| Line item | 2023-06 | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 |
|---|---|---|---|---|---|---|
| Total current assets | 11.62M | 9.83M | 8.11M | 6.59M | 4.90M | 2.36M |
| Cash & ST investments | 11.56M | -- | 7.96M | -- | 4.90M | -- |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 12.62M | 10.48M | 8.44M | 7.48M | 5.76M | 3.01M |
| Total current liabilities | 606.91K | -- | 193.58K | -- | 663.67K | -- |
| Short-term debt | 438.26K | -- | 59.81K | -- | 312.78K | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 632,320.00 | 312,554.00 | 219,512.00 | 763,839.00 | 895,308.00 | 1,794,003.00 |
| Total equity | 11.99M | 10.16M | 8.22M | 6.72M | 4.86M | 1.22M |
| Retained earnings | -17.32M | -- | -21.62M | -- | -25.20M | -- |
Cash flow
| Line item | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 409.90M | -390.99K | -726.57K | -767.31K | -5.27M | -4.96M | -4.00M | -3.11M |
| Depreciation & amortization | 249.70M | 0 | 9.52K | 26.46K | 604.40K | 769.69K | 745.59K | 392.74K |
| Free cash flow | 159.50M | -390.99K | -844.41K | -767.31K | -6.05M | -4.99M | -4.01M | -3.27M |
| Dividends paid | -138.90M | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 0 | 22.67M | -- | -- | -- |
| Ending cash balance | 228.80M | 243.31K | 386.98K | 59.41K | 6.42M | 1.56M | 2.96M | 2.42M |
| Line item | 2023-06 | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | -- | -- | -- | -- | -- | -- |
Returns & efficiency
| Line item | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -113.96 | -40.36 | -42.49 | -54.81 |
| ROA %i | 4.09 | -160.70 | -214.54 | -315.34 | -81.11 | -38.32 | -40.85 | -50.50 |
| ROIC %i | -- | -- | -- | -- | -83.28 | -38.71 | -41.37 | -52.29 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 8.59 | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | 5.04 | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.83 | 0.12 | 0.12 | 0.02 | 28.46 | 19.15 | 41.92 | 7.39 |
| Quick ratioi | 0.74 | 0.12 | 0.12 | 0.02 | 28.46 | 19.15 | 41.92 | 7.39 |
| Debt / assetsi | 86.08 | 855.64 | 597.24 | 1,082.51 | 4.28 | 3.67 | 1.02 | 9.46 |
| LT debt / equityi | -- | -- | -- | -- | 2.11 | 0.21 | 0.32 | 4.77 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 1.89 | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | 2.07 | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -6.04 | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2023-06 | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 |
|---|---|---|---|---|---|---|
| ROE %i | -40.36 | -37.89 | -42.49 | -48.33 | -54.81 | -177.66 |
| ROA %i | -38.32 | -36.20 | -40.85 | -45.55 | -50.50 | -134.35 |
| ROIC %i | -38.71 | -37.89 | -41.37 | -48.33 | -52.29 | -177.66 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 19.15 | -- | 41.92 | -- | 7.39 | -- |
| Quick ratioi | 19.15 | -- | 41.92 | -- | 7.39 | -- |
| Debt / assetsi | 3.67 | -- | 1.02 | -- | 9.46 | -- |
| LT debt / equityi | 0.21 | -- | 0.32 | -- | 4.77 | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 05:07:29 · For reference only, not investment advice and not tailored to your situation.